Boehringer has made a big push into RNA this month.
This opinion piece presents the opinions of the author. It does not necessarily reflect the views of BioSpace.
Boehringer Ingelheim made a big push into RNA in November, with two significant deals aimed at NASH (non-alcoholis steatohepatitis) and other liver disease. This mega-blockbuster indication is being pursued by a number of companies, but Boehringer thinks aiming at the RNA level could effectively block the abnormal accumulation of fat in the liver. The first deal, with Dicerna, is based on that company’s RNAi platform. The second, with MiNA Therapeutics, is based on that company’s small activating RNA technology, which it claims offers a unique (and well-patented) means of upregulating specific messenger RNA.
There was plenty more deal-making in November; look below for more key partnership news. -KT
Here’s a roundup of these stories and other top deals and partnerships from the past month.
- Tiny Zymeworks Snags $1.4B+ R&D Deal With Drug Giant Johnson & Johnson
- Bay Area’s Principia Biopharma Scores $765M MS Licensing Deal With Drug Giant Sanofi
- Banner ALZ’s Institute, Novartis, and Amgen Expand Collaboration in Pioneering ALZ’s Prevention Program
- Dicerna Could Pocket $201M in NASH R&D Deal With Boehringer Ingelheim
- Boehringer, MiNA Therapeutics Forge EUR 307M R&D NASH Tie-Up
Read More From Karl Thiel:
Are We Reaching the Biotech Singularity?
